Will (on for Matt Sykes)'s questions to Veracyte Inc (VCYT) leadership • Q1 2025
Question
Will, on for Matt Sykes, asked about the initial market response to the Decipher metastatic launch and its expected contribution for the remainder of the year.
Answer
CEO Marc Stapley described the initial response as 'exciting,' noting strong physician interest. CCO John Leite added that conversations at the recent AUA conference were very positive. CFO Rebecca Chambers clarified that while the launch is a contributor, its impact is already factored into the 2025 guidance, with the majority of growth still expected from the core biopsy market.